Recent approaches of lipid-based delivery system for lymphatic targeting via oral route

Journal of Drug Targeting

Volumn 22, Issue 10, 2014, Pages 871-882

  Chaudhary, Shilpa ^a   Garg, Tarun ^a   Murthy, R S R ^a   Rath, Goutam ^a   Goyal, Amit K ^a  

^a ISF COLLEGE OF PHARMACY   (India)

Author keywords

Chylomicron pathway; Lipid based delivery systems; Lymphatic delivery; Oral bioavailability

Indexed keywords

CHYLOMICRON INHIBITOR; ENZYME; LIPID; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; CHYLOMICRON; LIPOSOME; NANOPARTICLE;

ARTICLE; CACO 2 CELL LINE; CANNULATION; CASE STUDY; DIGESTION; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG TARGETING; DRUG TRANSPORT; ENZYME ACTIVITY; GASTRIC SUB MUCOSAL INJECTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTESTINE MUCOSA PERMEABILITY; INTRADERMAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAPLEURAL DRUG ADMINISTRATION; LIPOLYSIS; LYMPH VESSEL; LYMPHATIC SYSTEM; LYMPHATIC SYSTEM DISEASE; MESENTERIC LYMPH DUCT CANNULATION; NONHUMAN; ORAL DRUG ADMINISTRATION; SUBCUTANEOUS DRUG ADMINISTRATION; SUBMUCOSAL DRUG ADMINISTRATION; THORACIC DUCT; THORACIC LYMPH DUCT CANNULATION; ANIMAL; CHEMISTRY; METABOLISM; TRANSPORT AT THE CELLULAR LEVEL;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL TRANSPORT; CHYLOMICRONS; DRUG DELIVERY SYSTEMS; HUMANS; LIPIDS; LIPOSOMES; LYMPHATIC SYSTEM; NANOPARTICLES;

EID: 84910023561     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2014.950664     Document Type: Article

References (107)

1. Rockson SG. Lymphatic research: past, present, and future. Lymphat Res Biol 2009;7:183-7.
2. Ali Khan A, Mudassir J, Mohtar N, Darwis Y. Advanced drug delivery to the lymphatic system: lipid-based nanoformulations. Int J Nanomed 2013;8:2733-44.
3. Rubas W, Grass GM. Gastrointestinal lymphatic absorption of peptides and proteins. Adv Drug Deliv Rev 1991;7:15-69.
4. Garg T, Singh O, Arora S, Murthy R. Scaffold: a novel carrier for cell and drug delivery. Crit Rev Ther Drug Carrier Syst 2012;29: 1-63.
5. Trevaskis NL, Charman WN, Porter CJ. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Adv Drug Deliv Rev 2008;60:702-16.
6. Dahan A, Hoffman A. Evaluation of a chylomicron flow blocking approach to investigate the intestinal lymphatic transport of lipophilic drugs. Eur J Pharm Sci 2005;24:381-8.
7. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis in health and disease. Cancer cell 2002;1:219-27.
8. Goyal AK, Rath G, Garg T. Nanotechnological approaches for genetic immunization. In: Erdmann VA, Barciszewski J, eds. DNA and RNA nanobiotechnologies in medicine: diagnosis and treatment of diseases. Springer Berlin Heidelberg; 2013:67-120.
9. Kaur M, Garg T, Rath G, Goyal AK. Current nanotechnological strategies for effective delivery of bioactive drug molecules in the treatment of tuberculosis. Crit Rev Ther Drug Carrier Syst 2014; 31:49-88.
10. Goyal G, Garg T, Malik B, et al. Development and characterization of nano-fiber patch for the treatment of glaucoma. Eur J Pharm Sci 2014;53:10-16.
11. Garg T, Goyal AK. Biomaterial-based scaffolds-current status and future directions. Expert Opin Drug Deliv 2014;11:767-89.
12. Saraf S, Ghosh A, Kaur CD, Saraf S. Novel modified nanosystem based lymphatic targeting. Res J Nanosci Nanotechnol 2011;1: 60-74.
13. Goyal G, Garg T, Malik B, et al. Development and characterization of niosomal gel for topical delivery of benzoyl peroxide. Drug Deliv 2013. [Epub ahead of print].
14. Goyal G, Garg T, Rath G, Goyal AK. Current nanotechnological strategies for an effective delivery of drugs in treatment of periodontal disease. Crit Rev Ther Drug Carrier Syst 2014;31: 89-119.
15. Johal HS, Garg T, Rath G, Goyal AK. Advanced topical drug delivery system for the management of vaginal candidiasis. Drug Deliv 2014. [Epub ahead of print].
16. Kerjaschki D. The lymphatic vasculature revisited. J Clin Investig 2014;124:874-7.
17. Joshi D, Garg T, Goyal AK, Rath G. Advanced drug delivery approaches against periodontitis. Drug Deliv 2014. [Epub ahead of print].
18. Porter CJ, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov 2007;6:231-48.
19. Hultin M, Savonen R, Chevreuil O, Olivecrona T. Chylomicron metabolism in rats: kinetic modeling indicates that the particles remain at endothelial sites for minutes. J Lipid Res 2013;54: 2595-605.
20. Hultin M, Savonen R, Olivecrona T. Chylomicron metabolism in rats: lipolysis, recirculation of triglyceride-derived fatty acids in plasma FFA, and fate of core lipids as analyzed by compartmental modelling. J Lipid Res 1996;37:1022-36.
21. Zeng B-J, Mortimer B-C, Martins IJ, et al. Chylomicron remnant uptake is regulated by the expression and function of heparan sulfate proteoglycan in hepatocytes. J Lipid Res 1998;39: 845-60.
22. Singh H, Sharma R, Joshi M, et al. Transmucosal delivery of Docetaxel by mucoadhesive polymeric nanofibers. Artif Cells Nanomed Biotechnol 2014. [Epub ahead of print].
23. Kaur M, Malik B, Garg T, et al. Development and characterization of guar gum nanoparticles for oral immunization against tuberculosis. Drug Deliv 2014. [Epub ahead of print].
24. Sharma R, Singh H, Joshi M, et al. Recent advances in polymeric electrospun nanofibers for drug delivery. Crit Rev Ther Drug Carrier Syst 2014;31:187-217.
25. Armand M, Borel P, Ythier P, et al. Effects of droplet size, triacylglycerol composition, and calcium on the hydrolysis of complex emulsions by pancreatic lipase: an in vitro study. J Nutr Biochem 1992;3:333-41.
26. Kaur P, Garg T, Rath G, et al. Surfactant-based drug delivery systems for treating drug-resistant lung cancer. Drug Deliv 2014. [Epub ahead of print].
27. Carriere F, Barrowman J, Verger R, Laugier R. Secretion and contribution to lipolysis of gastric and pancreatic lipases during a test meal in humans. Gastroenterology 1993;105:876-88.
28. Tucci SA, Boyland EJ, Halford JC. The role of lipid and carbohydrate digestive enzyme inhibitors in the management of obesity: a review of current and emerging therapeutic agents. Diabetes Metab Syndr Obesity: Targets Ther 2010;3:125-43.
29. Napolitano M, Kruth HS, Bravo E. Phospholipase A2 mediates apolipoprotein-independent uptake of chylomicron remnant-like particles by human macrophages. Int J Vascular Med 2012;2012: 501954.
30. Kaur R, Garg T, Das Gupta U, et al. Preparation and characterization of spray-dried inhalable powders containing nanoaggregates for pulmonary delivery of anti-tubercular drugs. Artif Cells Nanomed Biotechnol 2014. [Epub ahead of print].
31. Koyama K, Hirao T, Toriba A, Hayakawa K. An analytical method for measuring a-amylase activity in starch-containing foods. Biomed Chromatogr 2013;27:583-8.
32. Marwah H, Garg T, Goyal AK, Rath G. Permeation enhancer strategies in transdermal drug delivery. Drug Deliv 2014. [Epub ahead of print].
33. Randolph GJ, Miller NE. Lymphatic transport of high-density lipoproteins and chylomicrons. J Clin Investig 2014;124:929-35.
34. Butkinaree C, Guo L, Ramkhelawon B, et al. A regulator of secretory vesicle size, Kelch-like protein 12, facilitates the secretion of apolipoprotein B100 and very-low-density lipoproteins-brief report. Arteriosclerosis Thrombosis Vascular Biol 2014;34:251-4.
35. Brunelli R, De Spirito M, Mei G, et al. Misfolding of apoprotein B-100, LDL aggregation and 17-beta-estradiol in atherogenesis. Curr Med Chem 2014;21:2276-83.
36. Jones MK, Zhang L, Catte A, et al. Assessment of the validity of the double superhelix model for reconstituted high density lipoproteins A combined computational-experimental approach. J Biol Chem 2010;285:41161-71.
37. Kaur R, Garg T, Malik B, et al. Development and characterization of spray-dried porous nanoaggregates for pulmonary delivery of anti-tubercular drugs. Drug Deliv 2014. [Epub ahead of print].
38. Sevick-Muraca EM, Kwon S, Rasmussen JC. Emerging lymphatic imaging technologies for mouse and man. J Clin Investigat 2014; 124:905-14.
39. Honnor A. Classification, aetiology and nursing management of lymphoedema. Brit J Nurs 2008;17:576-87.
40. Cisek P, Staros?awska E, Kieszko D, et al. [Lymphoedema-diagnosis and treatment]. Polski merkuriusz lekarski: Organ Polskiego Towarzystwa Lekarskiego 2013;35:370-4.
41. Brouillard P, Boon L, Vikkula M. Genetics of lymphatic anomalies. J Clin Invest 2014;124:898-904.
42. Adams KE, Rasmussen JC, Darne C, et al. Direct evidence of lymphatic function improvement after advanced pneumatic compression device treatment of lymphedema. Biomed Optics Express 2010;1:114-25.
43. Halin C, Detmar M. Inflammation, angiogenesis, and lymphangiogenesis. Methods Enzymol 2008;445:1-25.
44. Zhang Q, Lu Y, Proulx S, et al. Increased lymphangiogenesis in joints of mice with inflammatory arthritis. Arthritis Res Ther 2007;9:R118.
45. Fukui S, Takizawa Y, Kubota N, et al. Tuberculous lymphadenitis and the appearance of Behcet's disease-like symptoms. Internal Med (Tokyo, Japan), 2013;53:805-8.
46. Bur H, Haapasaari KM, Turpeenniemi-Hujanen T, et al. Oxidative stress markers and mitochondrial antioxidant enzyme expression are increased in aggressive Hodgkin lymphomas. Histopathology 2014. [Epub ahead of print].
47. Churchill WH, Rocklin RR, Moloney WC, David JR. In vitro evidence of normal lymphocyte function in some patients with Hodgkin's disease and negative delayed cutaneous hypersensitivity. Natl Cancer Institute Monograph 1973;36:99.
48. Tuscano JM, Dutia M, Chee K, et al. Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma. Brit J Haematol 2014;165:375-81.
49. Keating J, Yukich JO, Mollenkopf S, Tediosi F. Lymphatic filariasis and onchocerciasis prevention, treatment, and control costs across diverse settings: a systematic review. Acta Tropica 2014;135:86-95.
50. Reimer LJ, Thomsen EK, Tisch DJ, et al. Insecticidal bed nets and filariasis transmission in Papua New Guinea. N Engl J Med 2013; 369:745-53.
51. Singh O, Garg T, Rath G, Goyal AK. Microbicides for the treatment of sexually transmitted HIV infections. J Pharm 2014. [Epub ahead of print].
52. Maincent P, Thouvenot P, Amicabile C, et al. Lymphatic targeting of polymeric nanoparticles after intraperitoneal administration in rats. Pharm Res 1992;9:1534-9.
53. Akamo Y, Mizuno I, Yotsuyanagi T, et al. Chemotherapy targeting regional lymph nodes by gastric submucosal injection of liposomal adriamycin in patients with gastric carcinoma. Cancer Sci 1994;85:652-8.
54. Reddy ST, Van Der Vlies AJ, Simeoni E, et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol 2007;25:1159-64.
55. Puri N, Weyand EH, Abdel-Rahman SM, Sinko PJ. An investigation of the intradermal route as an effective means of immunization for microparticulate vaccine delivery systems. Vaccine 2000;18:2600-12.
56. Liu J, Scolland D, Reilly R, et al. Effect of particle size on the lymphatic distribution of 111indium-aminopolystyrene through intrapleural administration. Lymphology 2008;41:153-60.
57. Wang W, Chen N, Shen X, et al. Lymphatic transport and catabolism of therapeutic proteins after subcutaneous administration to rats and dogs. Drug Metab Dispos 2012;40:952-62.
58. Oussoren C, Zuidema J, Crommelin D, Storm G. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection: II. Influence of liposomal size, lipid composition and lipid dose. Biochim Biophys Acta (BBA)-Biomembranes 1997; 1328:261-72.
59. Roger E, Lagarce F, Benoit J-P. Development and characterization of a novel lipid nanocapsule formulation of Sn38 for oral administration. Eur J Pharm Biopharm 2011;79:181-8.
60. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997;15:110-15.
61. Trevaskis NL, Charman WN, Porter CJ. Targeted drug delivery to lymphocytes: a route to site-specific immunomodulation? Mol Pharm 2010;7:2297-309.
62. Fattal E, Tsapis N. Nanomedicine technology: current achievements and new trends. Clin Translational Imaging 2014;2:77-87.
63. Kim H, Kim Y, Lee J. Liposomal formulations for enhanced lymphatic drug delivery. Asian J Pharm Sci 2013;8:96-103.
64. Shete H, Chatterjee S, De A, Patravale V. Long chain lipid based tamoxifen NLC. Part II: Pharmacokinetic, biodistribution and in vitro anticancer efficacy studies. Int J Pharm 2013;454:584-92.
65. Beloqui A, Solin?s MA, Gascón AR, et al. Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier. J Control Release 2013;166:115-23.
66. Venkateswarlu V, Manjunath K. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Control Release 2004;95:627-38.
67. Cavalli R, Bargoni A, Podio V, et al. Duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin. J Pharm Sci 2003;92:1085-94.
68. Aji Alex M, Chacko A, Jose S, Souto E. Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting. Eur J Pharm Sci 2011;42:11-18.
69. Yang KY, Du Hyeong Hwang AMY, Kim DW, et al. Silymarinloaded solid nanoparticles provide excellent hepatic protection: physicochemical characterization and in vivo evaluation. Int J Nanomed 2013;8:3333.
70. Chen Y, Li G, Huang J, et al. Comparison of self-microemulsifying drug delivery system versus solid dispersion technology used in the improvement of dissolution rate and bioavailability of vinpocetine. Acta Pharmaceutica Sinica 2009;44:658-66.
71. Thakkar H, Nangesh J, Parmar M, Patel D. Formulation and characterization of lipid-based drug delivery system of raloxifenemicroemulsion and self-microemulsifying drug delivery system. J Pharm Bioallied Sci 2011;3:442.
72. Holm R, Porter CJ, Edwards GA, et al. Examination of oral absorption and lymphatic transport of halofantrine in a triple-cannulated canine model after administration in selfmicroemulsifying drug delivery systems (SMEDDS) containing structured triglycerides. Eur J Pharm Sci 2003;20:91-7.
73. Sun M, Zhai X, Xue K, et al. Intestinal absorption and intestinal lymphatic transport of sirolimus from self-microemulsifying drug delivery systems assessed using the single-pass intestinal perfusion (SPIP) technique and a chylomicron flow blocking approach: linear correlation with oral bioavailabilities in rats. Eur J Pharm Sci 2011;43:132-40.
74. Sha X, Wu J, Chen Y, Fang X. Self-microemulsifying drugdelivery system for improved oral bioavailability of probucol: preparation and evaluation. Int J Nanomed 2012;7:705-12.
75. Gürsoy RN, Ç evik O . Design, characterization and in vitro evaluation of SMEDDS containing an anticancer peptide, linear LyP-1. Pharm Dev Technol 2013;19:486-90.
76. Roger E, Lagarce F, Garcion E, Benoit J-P. Lipid nanocarriers improve paclitaxel transport throughout human intestinal epithelial cells by using vesicle-mediated transcytosis. J Control Release 2009;140:174-81.
77. Attili-Qadri S, Karra N, Nemirovski A, et al. Oral delivery system prolongs blood circulation of docetaxel nanocapsules via lymphatic absorption. Proc Natl Acad Sci 2013;110:17498-503.
78. Jain C, Vyas S, Dixit V. Niosomal system for delivery of rifampicin to lymphatics. Ind J Pharm Sci 2006;68:575-8.
79. Luo G, Yu X, Jin C, et al. LyP-1-conjugated nanoparticles for targeting drug delivery to lymphatic metastatic tumors. Int J Pharm 2010;385:150-6.
80. Sheue Nee Ling S, Magosso E, Abdul Karim Khan N, et al. Enhanced oral bioavailability and intestinal lymphatic transport of a hydrophilic drug using liposomes. Drug Dev Ind Pharm 2006; 32:335-45.
81. Iosio T, Voinovich D, Perissutti B, et al. Oral bioavailability of silymarin phytocomplex formulated as self-emulsifying pellets. Phytomedicine 2011;18:505-12.
82. Murota K, Cermak R, Terao J, Wolffram S. Influence of fatty acid patterns on the intestinal absorption pathway of quercetin in thoracic lymph duct-cannulated rats. Brit J Nutr 2013;109: 2147-53.
83. Paliwal R, Rai S, Vaidya B, et al. Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery. Nanomed: Nanotechnol Biol Med 2009;5: 184-91.
84. Nanjwade BK, Patel DJ, Udhani RA, Manvi FV. Functions of lipids for enhancement of oral bioavailability of poorly watersoluble drugs. Scientia Pharmaceutica 2011;79:705-27.
85. Porter CJ, Charman WN. Intestinal lymphatic drug transport: an update. Adv Drug Deliv Rev 2001;50:61-80.
86. Myers R, Stella V. Factors affecting the lymphatic transport of penclomedine (NSC-338720), a lipophilic cytotoxic drug: comparison to DDT and hexachlorobenzene. Int J Pharm 1992;80: 51-62.
87. Garnett M, Kallinteri P. Nanomedicines and nanotoxicology: some physiological principles. Occup Med 2006;56:307-11.
88. Rao DA, Forrest ML, Alani AW, et al. Biodegradable PLGA based nanoparticles for sustained regional lymphatic drug delivery. J Pharm Sci 2010;99:2018-31.
89. Patel HM. Serum opsonins and liposomes: their interaction and opsonophagocytosis. Crit Rev Ther Drug Carrier Syst 1992;9: 39-90.
90. Parnami N, Garg T, Rath G, Goyal AK. Development and characterization of nanocarriers for topical treatment of psoriasis by using combination therapy. Artif Cells Nanomed Biotechnol 2013. [Epub ahead of print].
91. Modgill V, Garg T, Goyal AK, Rath G. Permeability study of ciprofloxacin from ultra-thin nanofibrous film through various mucosal membranes. Artif Cells Nanomed Biotechnol 2014. [Epub ahead of print].
92. Buckley ST, Fischer SM, Fricker G, Brandl M. In vitro models to evaluate the permeability of poorly soluble drug entities: challenges and perspectives. Eur J Pharm Sci 2012;45:235-50.
93. Tong J, Wang Y, Chang B, et al. Evidence for the involvement of RhoA signaling in the ethanol-induced increase in intestinal epithelial barrier permeability. Int J Mol Sci 2013;14:3946-60.
94. Sahu SC, Zheng J, Graham L, et al. Comparative cytotoxicity of nanosilver in human liver HepG2 and colon Caco2 cells in culture. J Appl Toxicol 2014. [Epub ahead of print].
95. Vázquez M, Vélez D, Devesa V. In vitro characterization of the intestinal absorption of methylmercury using a Caco-2 cell model. Chem Res Toxicol 2014;27:254-64.
96. Dahan A, Hoffman A. The effect of different lipid based formulations on the oral absorption of lipophilic drugs: the ability of in vitro lipolysis and consecutive ex vivo intestinal permeability data to predict in vivo bioavailability in rats. Eur J Pharm Biopharm 2007;67:96-105.
97. Bolko K, Zvonar A, Gasperlin M. Simulating the digestion of lipid-based drug delivery systems (LBDDS): overview of in vitro lipolysis models. Acta Chim Slov 2014;61:1-10.
98. Boyd M, Risovic V, Jull P, et al. A stepwise surgical procedure to investigate the lymphatic transport of lipid-based oral drug formulations: cannulation of the mesenteric and thoracic lymph ducts within the rat. J Pharm Toxicol Methods 2004;49:115-20.
99. Phang K, Bowman M, Phillips A, Windsor J. Review of thoracic duct anatomical variations and clinical implications. Clin Anat 2014;27:637-44.
100. Lind ML, Jacobsen J, Holm R, Müllertz A. Intestinal lymphatic transport of halofantrine in rats assessed using a chylomicron flow blocking approach: the influence of polysorbate 60 and 80. Eur J Pharm Sci 2008;35:211-18.
101. Iqbal J, Dai K, Seimon T, et al. IRE1b inhibits chylomicron production by selectively degrading MTP mRNA. Cell metabolism 2008;7:445-55.
102. Ables GP, Yang KJZ, Vogel S, et al. Intestinal DGAT1 deficiency reduces postprandial triglyceride and retinyl ester excursions by inhibiting chylomicron secretion and delaying gastric emptying. J Lipid Res 2012;53:2364-79.
103. Xiao C, Dash S, Morgantini C, et al. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, acutely inhibits intestinal lipoprotein particle secretion in healthy humans. Diabetes 2014;62:2394-401.
104. Davidson MH, Voogt J, Luchoomun J, et al. Inhibition of intestinal cholesterol absorption with ezetimibe increases components of reverse cholesterol transport in humans. Atherosclerosis 2013;230:322-9.
105. Oliva J, French SW, Li J, Bardag-Gorce F. Proteasome inhibitor treatment reduced fatty acid, triacylglycerol and cholesterol synthesis. Exp Mol Pathol 2012;93:26-34.
106. Lin MC, Wang E-J, Lee C, et al. Garlic inhibits microsomal triglyceride transfer protein gene expression in human liver and intestinal cell lines and in rat intestine. J Nutr 2002;132: 1165-8.
107. Sajula B, Shah FM, Javed A, Alka A. Effect of poloxamer 188 on lymphatic uptake of carvedilol-loaded solid lipid nanoparticles for bioavailability enhancement. J Drug Target 2009;17:249-56.